Research Shows Chronix Technology Using Serum DNA Can Identify Early Presence Of Disease
Posted on: Tuesday, 23 June 2009, 10:56 CDT
Chronix Biomedical today reported that a new study in a peer-reviewed journal further confirms the potential diagnostic and prognostic utility of using circulating fragments of DNA to detect early stage disease. These DNA fragments, referred to as serum DNA, are released into the blood stream in trace amounts during the disease process. Chronix Biomedical has developed proprietary technology that can find, isolate and identify these serum DNA sequences, enabling very early detection of an underlying disease state or of a change in response to treatment. The study in the current issue of the journal Zoonoses & Public Health1 demonstrated that using Chronix technology, researchers were able to identify specific signature sequences in serum DNA before clinical symptoms appeared in animals experimentally infected with BSE (mad cow disease)."These new results add to the growing body of scientific data validating the value of serum DNA as an early indicator of disease, and also advance our unique ability to apply these findings to the development of laboratory tests for routine clinical use," said Howard Urnovitz, Ph.D., CEO of Chronix . "Using our proprietary technology and next-generation sequencers, we were able to identify distinctive DNA signatures indicating the presence of BSE in all of the infected animals well before clinical symptoms appeared."
These new findings follow three previous published studies demonstrating the utility of using serum DNA to identify human cancers, human infectious disease and BSE. For example, a study reported in the December issue of the journal Blood showed that serum DNA was able to identify a secondary cancer in a patient before it was clinically apparent.
Of special interest in this current study is the finding that these DNA signatures occurred primarily in non-coding regions of the genome, where geneticists typically would not look. Chronix scientists believe these findings may lead to a better understanding of the genetics of disease development, while advancing Chronix's own ability to harness these early changes for diagnostic and prognostic applications.
-----------------
On The Net:
BioCom Partners
Related Articles
- PAREXEL Enhances Early Phase Clinical Development Offering for Central Nervous System Studies
- Infant Judging Comes Early, Study Finds
- Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
- Nymox Announces New BPH Drug Long Term Follow-Up Study Clinical Data Presentation October 20 at American Urological Association Meeting
- Targeted Genetics to Host Conference Call to Discuss the Recombinant DNA Advisory Committee (RAC) Review and the tgAAC94 Clinical Program
- Early Impact of Texas Workers' Compensation Medical Fee Schedule Changes Identified in WCRI Study
- Power3 Medical Products Files Utility Patent Application on Discovery That Distinguishes Between Parkinson's and ALS; New Power3 Study Reveals Serum Biomarkers for Early ID of Parkinson's and ALS
- Cytori Therapeutics Reports Safety and Efficacy of Its Celution System(TM) in a Preclinical Study of Coronary Artery Disease; Outlines Design of Planned Chronic Ischemia Clinical Study in Europe
- Metabolon to Identify Disease Biomarkers for CDC Multiple Sclerosis Study
- Stability of Nucleosomal DNA Fragments in Serum
Rating: 2.7 / 5 (9 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds